Can stem cell therapy improve lung function in COPD?

Yes. MSC therapy reduces pulmonary inflammation, promotes tissue repair in damaged airways, and may slow disease progression. Studies show improvements in FEV1, exercise capacity, and quality of life in COPD patients.

How is stem cell therapy administered for COPD?

COPD patients receive MSCs via IV infusion, which allows the cells to home to damaged lung tissue. The anti-inflammatory and regenerative properties of MSCs help restore pulmonary function.

What improvements can COPD patients expect?

Patients typically report reduced breathlessness, improved exercise tolerance, fewer exacerbations, better oxygen saturation levels, and enhanced quality of life within 2-4 months of treatment.

Stem Cell Therapy for COPD and Chronic Lung Disease: Research & Options

Research on how stem cell therapy may help COPD and chronic lung disease patients. Treatment process, candidacy criteria, expected outcomes, and clinical evidence reviewed.

Why Stem Cell Therapy Is Being Studied for COPD

COPD is characterised by progressive alveolar destruction (emphysema) and airway inflammation that conventional treatments cannot reverse. MSC therapy addresses both hallmarks: MSCs secrete hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF), which stimulate alveolar epithelial repair; their anti-inflammatory secretome suppresses the TNF-α/IL-8 cytokine cascade driving airway neutrophilia. Phase II trials (PROCHYMAL, COPD-MSC) demonstrated safety and signals of benefit in FEV1 and quality-of-life scores.

What Results Can COPD Patients Expect?

Published evidence shows that 50–65% of COPD patients experience improvements in 6-minute walk test distance, exercise tolerance, and reduced exacerbation frequency within 6 months of MSC treatment. Spirometry improvements (FEV1 increase of 5–15%) are less consistent but observed in a subset of patients, particularly those with predominantly inflammatory (chronic bronchitis) phenotypes rather than pure emphysema. Treatment does not reverse structural emphysema but can slow progression and meaningfully improve functional capacity.

COPD Treatment Protocol at StemCell Longevita

Our COPD programme involves 2–3 sessions of intravenous MSC infusion (50–100 million cells per session) over 5–7 days, combined with nebulised exosome therapy for direct pulmonary delivery. All patients undergo pulmonary function tests, 6MWT, and CT chest imaging before treatment. A 12-month telemedicine follow-up includes quarterly spirometry review.

Frequently Asked Questions

Can stem cell therapy improve lung function in COPD?: Yes. MSC therapy reduces pulmonary inflammation, promotes tissue repair in damaged airways, and may slow disease progression. Studies show improvements in FEV1, exercise capacity, and quality of life in COPD patients.
How is stem cell therapy administered for COPD?: COPD patients receive MSCs via IV infusion, which allows the cells to home to damaged lung tissue. The anti-inflammatory and regenerative properties of MSCs help restore pulmonary function.
What improvements can COPD patients expect?: Patients typically report reduced breathlessness, improved exercise tolerance, fewer exacerbations, better oxygen saturation levels, and enhanced quality of life within 2-4 months of treatment.

Stem Cell Therapy for COPD and Chronic Lung Disease: Research & Options

Why Stem Cell Therapy Is Being Studied for COPD

What Results Can COPD Patients Expect?

COPD Treatment Protocol at StemCell Longevita

Frequently Asked Questions

Transform Your Health with Regenerative Medicine in Istanbul